INTRODUCTION

Gastric cancer has the sixth highest incidence and the third most common cause of death from cancer worldwide. The World Health Organization estimates that gastric cancer accounted for 1,033,701 new cases and 782,685 deaths worldwide in 2018. Tremendous geographic variation exists regarding the incidence of gastric cancer worldwide. Disease incidence is low in North America and Northern Europe and highest in Asian countries (i.e., Mongolia, Japan, and South Korea). The highest death rates were recorded in Western Asian countries (Iran, Turkmenistan, and Kyrgyzstan).

RESEARCH ARTICLE

Combination of artificial intelligence-based endoscopy and miR148a methylation for gastric indefinite dysplasia diagnosis

Yoshiyuki Watanabe1,2,3 | Ritsuko Oikawa1 | Shuhei Agawa3 | Yasumasa Matsuo1 | Ichiro Oda2 | Seiji Futagami3 | Hiroyuki Yamamoto4 | Tomohiro Tada5 | Fumio Itoh1

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
2Department of Internal Medicine, Kawasaki Rinko General Hospital, Kanagawa, Japan
3Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
4Department of Bioinformatics, St. Marianna University Graduate School of Medicine, Kanagawa, Japan
5Tada Tomohiro Institute of Gastroenterology and Proctology, Taitama, Japan

Correspondence
Yoshiyuki Watanabe, Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao Miyamae-ku, Kawasaki-city, Kanagawa 216-8511, Japan. Email: ponpon@Marianna-u.ac.jp

Funding information
Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant/Award Number: #18K15764, #19H03521, #19H03568 and #21K07901; Grants-in-Aid for Scientific Research from the New Energy and Industrial Technology Development Organization, Grant/Award Number: #19194859

Abstract

Background and Aim: Gastrointestinal endoscopy and biopsy-based pathological findings are needed to diagnose early gastric cancer. However, the information of biopsy specimen is limited because of the topical procedure; therefore, pathology doctors sometimes diagnose as gastric indefinite for dysplasia (GIN).

Methods: We compared the accuracy of physician-performed endoscopy (trainee, n = 3; specialists, n = 3), artificial intelligence (AI)-based endoscopy, and/or molecular markers (DNA methylation: BARHL2, MINT31, TET1, miR-148a, miR-124a-3, NKX6-1; mutations: TP53; and microsatellite instability) in diagnosing GIN lesions. We enrolled 24,388 patients who underwent endoscopy, and 71 patients were diagnosed with GIN lesions. Thirty-two cases of endoscopic submucosal dissection (ESD) in 71 GIN lesions and 32 endoscopically resected tissues were assessed by endoscopists, AI, and molecular markers to identify benign or malignant lesions.

Results: The board-certified endoscopic physicians group showed the highest accuracy in the receiver operative characteristic curve (area under the curve [AUC]: 0.931), followed by a combination of AI and miR148a DNA methylation (AUC: 0.825), and finally trainee endoscopists (AUC: 0.588).

Conclusion: AI with miR148s DNA methylation-based diagnosis is a potential modality for diagnosing GIN.

KEYWORDS
artificial intelligence, endoscopy, DNA methylation, gastric indefinite dysplasia, gastric cancer, endoscopy, molecular markers
Endoscopic screening in Asian countries has reduced gastric cancer mortality. Early diagnosis increases the five-year survival rate to >90%. However, early gastric cancer may be difficult to endoscopically diagnose (4.6–25.8% false-negative rates). Candidate molecular markers (ie, methylation, mutation, and microsatellite instability [MSI]) have been reported as accurate markers to detect early gastric cancer. Artificial intelligence (AI)-based endoscopy has vast medical applications.

We aimed to compare and evaluate the diagnostic sensitivity and specificity of physician-performed endoscopy, AI-based endoscopy, and/or molecular markers in detecting gastric indefinite dysplasia (GIN).

2 | MATERIALS AND METHODS

2.1 | Patients, endoscopy, clinical samples, and DNA extraction

We enrolled a total of 24,388 patients who underwent endoscopy between April 2010 and March 2013 at St. Marianna University School of Medicine Hospital, Japan. A total of 6788 patients underwent gastric biopsy, and 71 underwent gastric biopsy after EGD for GIN (Category 2 according to the Vienna Classification of GIN). Under informed consent with patient and their family, 32 patients agreed to endoscopic resection for detail and accurate diagnosis but also treatment. We successfully performed endoscopic submucosal resection (ESD) in all cases by two expert (board-certified) endoscopists, and 32 endoscopically resected tissues were used as a reference for the final pathological diagnosis. GIN diagnosis was classified according to (a) few atypical cells, (b) erosion and/or inflammation, and (c) tissue damage. The EGD was performed by endoscopists, including both trainee and board-certified physicians using a single gastrointestinal endoscope (GIF H260, GIF Q260, and GIF H-260Z; Olympus Medical Systems, Co., Ltd.). The endoscopically resected tissues of the GIN lesions (histologic specimen) were fixed in formalin, and the histopathological characteristics of the studied samples were paraffin-embedded. Genomic DNA of 32 samples was extracted from each FFPE tissue using the standard phenol/chloroform method. This study was reviewed and approved by the Ethics Committee of the St. Marianna University School of Medicine (No. #3345).

2.2 | Candidate molecular marker analysis

Bisulfite polymerase chain reaction (PCR) and quantitative promoter DNA methylation analysis of pyrosequencing of candidate genes (BARHL2, MINT31, TET1, miR-148a, miR-124a-3, NKX6-1) were performed using an EpiTect Bisulfite kit (Qiagen) and Pyromark Advanced Q24 system (Qiagen). Pyrosequencing quantitatively measures the methylation status of several CpG sites in each gene promoter. These adjacent sites usually show highly concordant methylation patterns. Therefore, the mean percentage of methylation at the detected sites was used as a representative value for the gene promoter. All primers and protocols were based on previous reports. TP53 mutation analysis was performed and decided using immunohistochemistry (Anti-TP53 [DO-7] antibody). MSI analysis also was performed as previously described.

2.3 | Constructing a convolution neural network (CNN) algorithm

To construct an AI-based diagnostic system, we used a deep neural network architecture called the single-shot multibox detector (SSD) (http://arxiv.org/abs/1512.02325), without altering its algorithm. SSD is a deep CNN that consists of ≥16 layers. The Caffe deep learning framework was then used to train, validate, and test the CNN. All CNN layers were fine-tuned using stochastic gradient descent with a global learning rate of 0.0001. Each image was resized to 300 pixels x 300 pixels. The bounding box was also resized accordingly to optimize CNN analysis. These values were set up by trial and error to ensure that all data were compatible with SSD (AI Medical Service Inc.).

2.4 | Outcome measures of AI-based detection and diagnosis

A total of 2961 images from 32 cases were collected. There were some images that were unsuitable for consideration (GIN lesion was not in the image, out of focus images, blurry images, halation affect). Thus, two expert (board-certified) endoscopist carefully selected 248 images finally that showed the GIN lesion without any issues. ESD in all cases was performed by two expert (board-certified) endoscopist. When the CNN detected a gastric mucosal abnormality in the lesion for all images, the CNN encodes a disease name (non-tumorous lesion or tumorous lesion [cancer and/or adenoma]) and its position. The detected lesion was identified by a yellow rectangular frame on the endoscopic images, and the degree of reliability was calculated according to the measured result of the CNN.

2.5 | Statistical analysis

All statistical analyses were performed using the SPSS for Windows (v.12. (SPSS, Inc.) and PRISM for Windows (v.7. (GraphPad Software). All reported p-values were two-sided, and statistical significance was set at p < 0.05. We computed the median DNA methylation value and range for each sample, and we defined the receiver operating characteristic (ROC) curve using SPSS. The z-score analysis was used to normalize the methylation levels of several genes, microsatellite instability (MSI), TP53 gene mutation status, AI diagnosis, and endoscopist’s diagnosis in each sample. The z-score of the methylation for each gene was calculated as follows: z-score = (methylation level of each sample – mean value of methylation level)/standard deviation of methylation.
level. In this analysis, a z-score >0 indicates that the methylation level is greater than the mean value for the population.

3 | RESULTS

3.1 | Clinical characteristics and endoscopic images of all cases, lesions

All endoscopic images of abnormal (indeterminate) lesions from the 32 cases of ESD histopathologically confirmed GIN were analyzed for AI diagnosis. Examples of the endoscopic images are shown in Figure 1A. The clinical characteristics of all cases are shown in Figure 1B and Table 1.

3.2 | Clinical diagnostic ability of AI, molecular markers, and endoscopist

We first calculated the individual diagnostic ability of AI, molecular markers, and two endoscopists using the area under the curve (AUC) of the ROC curve in Figure 2.

AI detected 96.9% of the cases (31/32) of GIN lesions and diagnosed as TURE (neoplastic lesion) or FALSE (non-neoplastic lesion). We observed a sensitivity of 75.0% and specificity of 50% (AUC, 0.701) for the AI diagnostic power referenced from pathological findings after ESD (Figure 2A). In genetic alteration of TP53 gene mutation analysis, we found 12 positive cases via immunohistochemistry (IHC) staining using a TP53 antibody (37.5%, 12/32) even in non-neoplastic lesions (Figure 3A, Table 1). In the MSI analysis, we found MSI-H/MSI-L cases (9.4%, 3/32) in only non-neoplastic lesions using 5 MSI markers (BAT-25, BAT-26, NR-21, NR-24, MONO-27) (Figure 3B, Table 1). On DNA methylation analysis, we found a sensitivity of 75.0% and specificity of 50.0% for BARHL2 (AUC, 0.425); 75.0% and 40.0%, respectively, for P16 (AUC, 0.701); 25.0% and 40.0%, respectively, for MINT31 (AUC, 0.175); 75.0% and 40.0%, respectively, for TET1 (AUC, 0.325); 100.0% and 80.0%, respectively, for miR148a (AUC, 0.825); 50.0% and 10.0%, respectively, for miR124a3 (AUC, 0.150); and 50.0% and 30.0%, respectively, for NKX6-1 (AUC, 0.238) (Figure 3C, Table 1).

The best AUC was for the biomarker miR148a DNA methylation (AUC, 0.792), followed by AI (AUC, 0.701) (Figure 2A). We then calculated the diagnostic ability of AI when combined with the other two factors. The best AUC was for AI + miR148a (AUC: 0.825) as...
### TABLE 1  
Detail results of the clinical characteristics, molecular markers (immunohistochemistry, microsatellite instability, and methylation), and artificial intelligence diagnosis in 32 cases of endoscopic submucosal dissection

| Gender | Age | Location | Tumor shape (Macroscopic types) | With ulcer (UL) | Tumor size (mm) | Mutation | Microsatellite markers (Allele 1/ Allele 2) |
|--------|-----|----------|---------------------------------|-----------------|----------------|----------|---------------------------------------------|
| Male   | 59  | L GC     | Slightly elevated               |                 | 12             | Mut      | BAT-25 BR-25 NR-21 NR-24 MONO-27            |
| Female | 69  | L AW     | Depressed                       |                 | 20             | Mut      | MSH-H                                       |
| Male   | 76  | M AW     | Flat                            |                 | 22             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 69  | M AW     | Depressed                       |                 | 15             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Male   | 72  | L PW     | Depressed                       | +               | 25             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Male   | 70  | L GC     | Depressed                       |                 | 10             | WT       | MSH-L                                       |
| Female | 55  | L AW     | Depressed                       |                 | 8              | WT       | (-) (-) (-) (-) (-) (-)                  |
| Female | 73  | M LC     | Depressed                       | +               | 18             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 86  | L LC     | Depressed                       |                 | 25             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Male   | 69  | M GC     | Slightly elevated               |                 | 19             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 71  | U PW     | Depressed                       |                 | 15             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 83  | U LC     | Flat                            |                 | 12             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 60  | L PW     | Depressed                       | +               | 20             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 68  | L LC     | Flat                            |                 | 10             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Male   | 70  | L PW     | Depressed                       |                 | 8              | Mut      | MSH-L                                       |
| Male   | 75  | L AW     | Slightly elevated               |                 | 20             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Female | 70  | M GC     | Flat                            |                 | 12             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Female | 71  | L AW     | Depressed                       |                 | 20             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 74  | U LC     | Slightly elevated               |                 | 10             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Female | 78  | U LC     | Slightly elevated               |                 | 28             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 71  | M LC     | Depressed                       |                 | 12             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Female | 78  | U AW     | Depressed                       |                 | 10             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Female | 81  | U PW     | Depressed                       |                 | 10             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 72  | L PW     | Depressed                       |                 | 9              | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 81  | L LC     | Slightly elevated               |                 | 15             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Male   | 78  | U PW     | Depressed                       |                 | 12             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 79  | L PW     | Depressed                       |                 | 10             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 73  | M PW     | Depressed                       |                 | 10             | Mut      | (-) (-) (-) (-) (-) (-)                  |
| Male   | 74  | L AW     | Depressed                       | +               | 14             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 66  | L LC     | Slightly elevated               |                 | 12             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Female | 64  | L AW     | depressed                       |                 | 10             | WT       | (-) (-) (-) (-) (-) (-)                  |
| Male   | 81  | L LC     | Depressed                       |                 | 9              | Mut      | (-) (-) (-) (-) (-) (-)                  |

Note: Gray shaded area are title of diagnostic factors.
All bold values are important factors for diagnosis.
TRUE, AI diagnosed as a neoplastic lesion, FALSE, AI diagnosed as a non-neoplastic lesion.
AW, anterior wall; BARHL2, BarH like homeobox 2; GC, greater curvature; L, lower 1/3 of the stomach; LC, lesser curvature; M, middle 1/3 of the stomach; MINT31, methylation in tumor 31; miR148a, microRNA 148a; MSI-H, microsatellite instability high; MSI-L, microsatellite instability low; Mut, mutation; NXX6-1, NXX homeobox 1; p16, cyclin-dependent kinase inhibitor 2A; PW, posterior wall; TET1, Tet methylcytosine dioxygenase 1; U, upper 1/3 of the stomach; WT, wild type.
### DNA methylation markers (%)

| BARHL2 | P16 | MINT31 | TET1 | miR148a | miR124a3 | NKX6-1 | AI diagnosis | Pathological findings after ESD endoscopic treatment |
|--------|-----|--------|------|---------|----------|--------|--------------|-----------------------------------------------------|
|        | 8   | —      | 21   | 24      | 38       | 74     | TURE        | Neoplastic lesion                                   |
| 81     | 7   | 1      | 11   | 14      | 51       | 91     | FALSE       | Non-neoplastic lesion                               |
|        | —   | —      | 9    | 29      | 16       | 29     | 2           | Non-neoplastic lesion                               |
| 41     | 7   | 11     | 18   | 28      | 33       | 40     | FALSE       | Non-neoplastic lesion                               |
| 30     | 6   | 6      | 13   | 24      | 32       | 42     | TURE        | Neoplastic lesion                                   |
|        | 1   | —      | 18   | 20      | 17       | 76     | FALSE       | Non-neoplastic lesion                               |
| 53     | 6   | 13     | 14   | 23      | 37       | 39     | FALSE       | Non-neoplastic lesion                               |
| 44     | 4   | 7      | 15   | 23      | 40       | 57     | FALSE       | Non-neoplastic lesion                               |
| 64     | 3   | 1      | 4    | 28      | 29       | 44     | TURE        | Neoplastic lesion                                   |
| 34     | 4   | 15     | 11   | 15      | 38       | 52     | FALSE       | Non-neoplastic lesion                               |
|        | —   | —      | 1    | 10      | 38       | —      | TURE        | Non-neoplastic lesion                               |
| 49     | 1   | 1      | 13   | 15      | 66       | 96     | FALSE       | Non-neoplastic lesion                               |
|        | —   | —      | 3    | 17      | 66       | 96     | TURE        | Neoplastic lesion                                   |
| 98     | 7   | 16     | 10   | 18      | 50       | 65     | FALSE       | Non-neoplastic lesion                               |
|        | —   | —      | 73   | 28      | 56       | —      | FALSE       | Non-neoplastic lesion                               |
|        | 77  | 22     | 85   | —       | —        | TURE   | Neoplastic lesion                                   |
| 39     | 7   | 1      | 17   | 1       | —        | FALSE   | Non-neoplastic lesion                               |
|        | —   | 0      | 22   | —       | —        | TURE   | Neoplastic lesion                                   |
|        | —   | —      | 1    | 24      | 83       | —      | TURE        | Neoplastic lesion                                   |
|        | —   | —      | 1    | 22      | —        | —      | Undecidable | Non-neoplastic lesion                               |
| 98     | 6   | 0      | 13   | 14      | 71       | 58     | FALSE       | Non-neoplastic lesion                               |
| 24     | 7   | 3      | 16   | 26      | 36       | 41     | TURE        | Non-neoplastic lesion                               |
|        | —   | —      | 3    | 20      | 18       | —      | TURE        | Neoplastic lesion                                   |
| 52     | 16  | 0      | 12   | 24      | 48       | 44     | TURE        | Neoplastic lesion                                   |
| 99     | 4   | 13     | 14   | 17      | 50       | 57     | FALSE       | Non-neoplastic lesion                               |
|        | 1   | 1      | 7    | 24      | 50       | 99     | TURE        | Neoplastic lesion                                   |
|        | 3   | 0      | 8    | 16      | 49       | —      | TURE        | Neoplastic lesion                                   |
|        | —   | —      | 7    | 20      | 2        | —      | TURE        | Neoplastic lesion                                   |
|        | —   | —      | 10   | 30      | 12       | —      | TURE        | Neoplastic lesion                                   |
| 99     | —   | —      | 1    | 22      | 84       | —      | TURE        | Neoplastic lesion                                   |
| 50     | 12  | 0      | 14   | 28      | 34       | 39     | TURE        | Neoplastic lesion                                   |
shown in Figure 2B. Interestingly, the diagnostic power of the AI + miR148a combination was located between the diagnostic power of board-certified endoscopists (AUC: 0.931) and trainees (AUC: 0.588) (Figure 2C).

4 | DISCUSSION

Gastric cancer has the sixth highest incidence and the third most common cause of death from cancer worldwide. However, early gastric cancer may be difficult to endoscopically diagnose. Candidate molecular markers (ie, methylation, mutation, and MSI) have been reported as accurate markers to detect early gastric cancer.

Image recognition using AI has dramatically improved due to innovative technologies such as machine learning and deep learning. These techniques are now being applied to gastrointestinal endoscopy worldwide. AI has high diagnostic accuracy for esophageal, gastric, and colorectal cancers. However, AI has been mostly used to identify irregular or malignant lesions. Qualitative investigations for a comprehensive diagnosis to facilitate appropriate therapy remain limited. Despite direct visualization of the lesion during endoscopy, findings can be difficult to classify as benign irregular lesions (ulcers, infections, or other factors) or malignant even in using additional narrow band imaging, red dichromatic imaging, extended depth of field, and magnified view functions (Figure 1C). Post-endoscopy, biopsy remains essential for clinicians for a definitive diagnosis and to formulate a treatment plan. Despite the availability of both endoscopic and histologic diagnosis, differentiating between benign and malignant lesions is still challenging; some lesions are classified indeterminately as GIN. One reason is the difficulty of evaluating the entire lesion pathologically using only a fragment of tissue. In some cases, patient consent is obtained to perform minimally invasive ESD for both therapeutic and diagnostic purposes. This makes it possible to perform a histological assessment of the entire lesion to determine whether it is benign or malignant. Conventionally, it is ideal to assess ESD.

Mechanisms of malignant transformation due to genetic abnormalities include driver gene mutations and the accumulation of passenger gene abnormalities due to epigenetic alterations including DNA and microRNA methylation. In gastric cancer, the accumulation of abnormalities due to epigenetic gene alterations from Helicobacter pylori infection is important in tumorigenesis.
Multiple studies have investigated the clinical applications of these candidate molecular markers for diagnosis; while the "risk and predictive diagnoses" for malignant gastric transformation has been achieved, its practical applications to diagnose the presence, site, and extent of lesions have not been sufficiently realized. AI diagnosis, which involves assessments based on various data on the surface of the lesion, is gaining popularity because it enables the non-invasive diagnosis of the presence, site, and extent of lesions (Figure 1C). The diagnostic capacity of AI for gastric cancer has been reported superior to that of endoscopists in training, and at par with specialists (board-certified endoscopic physicians). We used AI diagnosis alone or in combination with molecular markers (methylation, mutation, MSI) and endoscopic diagnosis in 32 patients who underwent ESD with a preoperative pathological diagnosis of GIN to perform retrospective single factor and multifactor assessments with ROC. We observed that the accuracy for GIN diagnosis from the combination of miR-148a and AI was extremely high. The AUC results were second only to certified endoscopists for diagnosing GIN lesions. This high accuracy may be due to the combined benefits of AI (surface information) in its ability to diagnose the presence, site, and range of the entire lesion and the accuracy of the molecular marker (cell information). This overcomes the limitation of histologic diagnosis that uses only limited tissue samples (Figure 1C).

Digital technology is already expanding in the medical field, even in the clinical diagnosis of gastric cancer. Clinicians often use endoscopy for diagnosis not only with white light, but also with a digital magnified function and narrow banding imaging function. Indigo carmine staining is also a helpful tool for diagnosis; however, it does not have enough diagnostic power for gastric cancer, especially for tiny lesions and any artifact lesions (biopsy scar, H. pylori infection, ulceration, inflammation, or drug effect) even when used by an expert endoscopist. AI diagnosis may have the potential to support endoscopists of all skill levels and may also be helpful to shorten the learning curve for trainee endoscopists. Moreover, we speculate that a combination of molecular markers may not only be useful for a more detailed assist diagnosis, but may also be an auxiliary tool for therapeutic strategies.

Our study has several limitations. This study only examined a relatively small sample size using a limited number of genetic markers. Going forward, more studies involving a comprehensive gene search are needed.
ACKNOWLEDGMENTS
This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to Y.W. (#21K07901), R.O. (#18K15764), H.Y. (#19H03521), and F.I. (#19H03568). Grants-in-Aid for Scientific Research from the New Energy and Industrial Technology Development Organization to T.T, S.F. and Y.W. (#19J194859). We thank Dr. Nobue Ueki as an endoscopic diagnosis support.

CONFLICT OF INTEREST
The authors disclose no conflict of interest.

AUTHOR CONTRIBUTIONS
Watanabe Y, Oikawa R, and Matsuo Y designed and coordinated the study and performed the experiments, acquired, and analyzed data; Watanabe Y, Oikawa R, Agawa S, Matsuo Y, Tada T, and Yamamoto H interpreted the data; Watanabe Y, Oikawa R and Futagami S validated mutant strains using bioinformatics approach; Futagami S, Oda I, Yamamoto H, and Itoh F wrote or edited the manuscript; all authors approved the final version of the article.

APPROVAL CODE ISSUED BY THE INSTITUTIONAL REVIEW BOARD (IRB)
This study was reviewed and approved by the Ethics Committee of the St. Marianna University School of Medicine (No. #3345).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Yoshiyuki Watanabe https://orcid.org/0000-0001-9037-3596
Ritsuko Oikawa https://orcid.org/0000-0003-0444-0081

REFERENCES
1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953. doi:10.1002/ijc.31937
2. Zhang X, Li M, Chen S, et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroneterology. 2018;155:347-354.e9
3. Menon S, Trudgill N. How commonly is upper gastrointestinal neoplasm detection rates based on inspection time and esophagastroduodenoscopy training. Endosc Int Open. 2018;06:E1190-E1197.
4. Hosokawa O, Tsuda S, Kidani E, et al. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy. 1998;30:669-674.
5. Yalamarthi S, Witherspoon P, McColle D, Auld CD. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy, 2004;36:874-879.
6. Yoshimizu S, Hirasawa T, Horiiuchi Y, et al. Differences in upper gastrointestinal neoplasm detection rates based on inspection time and esophagastroduodenoscopy training. Endosc Int Open. 2018;06:E1190-E1197.
7. Sano T, Koder N. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112.
8. Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut. 2002;51:130-131.
9. Yamamoto H, Watanabe Y, Oikawa R, et al. BARHL2 methylation using gastric wash DNA or gastric juice exosomal DNA is a useful marker for early detection of gastric cancer in an H. pylori-independent manner. Clin Transl Gastroenterol. 2016;7(7):e184. doi:10.1038/ctg.2016.40
10. Watanabe Y, Kim HS, Castoro R, et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroneterology. 2009;136(7):2149-2158. doi:10.1053/j.gastro.2009.02.085
11. Yatagai N, Saito T, Akazawa Y, et al. TP53 inactivation and expression of methylation-associated proteins in gastric adenocarcinoma with enteroblastic differentiation. Virchows Arch. 2019;474:315-324.
12. Sakamoto N, Naito Y, Oue N, et al. MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis. Cancer Sci. 2014;105:236-243.
13. Ando T, Yoshida T, Enomoto S, et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009;124:2367-2374.
14. Asada K, Nakajima T, Shimazu T, et al. Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut. 2015;64:388-396.
15. Yamamoto H, Watanabe Y, Maehata T, Imai K, Itoh F. Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach. Arch Toxicol. 2020. Springer Science and Business Media Deutschland GmbH, 94:3349-3357.
16. Hirasawa T, Aoyama K, Tanimoto T, et al. Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images. Gastric Cancer. 2018;21:653-660.
17. Hirasawa T, Yoshio T, Tada T. Current status of AI diagnosis in upper gastrointestinal tract. J Japanese Soc Gastroenterol. 2020;117:141-149.
18. Hirasawa T, Ikenoyama Y, Ishioka M, et al. Current status and future perspective of artificial intelligence applications in endoscopic diagnosis and management of gastric cancer. Dig Endosc. 2021;33:263-272.
19. Nam HS, Choi CW, Kim SJ, et al. Endoscopic submucosal dissection for gastric indefinite for neoplasia: which lesions should be resected? Surg Endosc. 2019;33:3976-3983.
20. Matsuo Y, Yasuda H, Kato M, et al. Endoscopic small-capacity forceps increase the pathological diagnosis of gastric indefinite neoplasm. Turkish J Gastroenterol. 2018;29:481-487.
21. Ono S, Kato M, Ono Y, et al. Target biopsy using magnifying endoscopy in clinical management of gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol. 2011;26(7):1133-1138. doi:10.1111/j.1440-1446.2011.06729.x
22. Oda I, Shimazu T, Ono H, et al. Design of Japanese multicenter prospective cohort study of endoscopic resection for early gastric cancer using Web registry (J-WEB/EGC). Gastric Cancer. 2012;15:451-455.
23. Watanabe Y, Kato N, Maehata T, et al. Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration. J Gastroenterol Hepatol. 2009;21(11):1675-1680. doi:10.1111/j.1440-1446.2009.06679.x
24. Ushijima T, Suzuki H. The origin of CIMP, at last. J Gastroenterol Hepatol. 2011;26(7):1133-1138. doi:10.1111/j.1440-1446.2011.06729.x
25. Yamamoto H, Watanabe Y, Maehata T, et al. An updated review of gastric cancer in the next-generation sequencing era: insights
from bench to bedside and vice versa. *World J Gastroenterol.* 2014;20:3927-3937.

28. Miyamoto S, Watanabe Y, Oikawa R, et al. Analysis of Helicobacter pylori genotypes in clinical gastric wash samples. *Tumor Biol.* 37(8):10123-10132. doi:10.1007/s13277-016-4886-4

29. Watanabe Y, Oikawa R, Kodaka Y, et al. Cancer-related genetic variants of Helicobacter pylori strains determined using gastric wash-based whole-genome analysis with single-molecule real-time technology. *Int J Cancer.* 2021;148(1):178-192. doi:10.1002/ijc.33257

30. Kusano M, Toyota M, Suzuki H, et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein–Barr virus. *Cancer.* 2006;106(7):1467-1479. doi:10.1002/cncr.21789

31. Suzuki H, Yamamoto E, Nojima M, et al. Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. *Carcinogenesis.* 2010;31(12):2066-2073. doi:10.1093/carcin/bgq203

32. Pereira AL, Magalhães L, Moreira FC, et al. Epigenetic field carcinization in gastric cancer: MicroRNAs as promising biomarkers. *J Cancer.* 2019;10:1560-1569.

**How to cite this article:** Watanabe Y, Oikawa R, Agawa S, et al. Combination of artificial intelligence-based endoscopy and miR148a methylation for gastric indefinite dysplasia diagnosis. *J Clin Lab Anal.* 2022;36:e24122. [https://doi.org/10.1002/jcla.24122](https://doi.org/10.1002/jcla.24122)